Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 5:02 PM View:  | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 01-Apr-24 | Payment of Exercise | 1,004 | $3.08 | $3,092.32 | (< 1%) 495.16K to 494.16K | |
| 03-Apr-24 5:04 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 01-Apr-24 | Payment of Exercise | 161 | $3.08 | $495.88 | (< 1%) 149.44K to 149.27K | |
| 03-Apr-24 5:06 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 01-Apr-24 | Payment of Exercise | 157 | $3.08 | $483.56 | (< 1%) 133.9K to 133.74K | |
| 03-Apr-24 5:08 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 01-Apr-24 | Payment of Exercise | 94 | $3.08 | $289.52 | (< 1%) 131.84K to 131.74K | |
| 03-Jan-24 5:20 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 02-Jan-24 | Payment of Exercise | 161 | $2.28 | $367.08 | (< 1%) 149.6K to 149.44K | |
| 03-Jan-24 5:21 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 02-Jan-24 | Payment of Exercise | 157 | $2.28 | $357.96 | (< 1%) 134.06K to 133.9K | |
| 03-Jan-24 5:22 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 02-Jan-24 | Payment of Exercise | 93 | $2.28 | $212.04 | (< 1%) 131.93K to 131.84K | |
| 03-Jan-24 5:17 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 02-Jan-24 | Payment of Exercise | 1,004 | $2.28 | $2,289.12 | (< 1%) 496.17K to 495.16K | |
| 03-Jan-24 5:17 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 01-Jan-24 | Grant | 225,000 | -- | -- | 83% 271.17K to 496.17K | |
| 03-Jan-24 5:20 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 01-Jan-24 | Grant | 62,500 | -- | -- | 72% 87.1K to 149.6K | |
| 03-Jan-24 5:21 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 01-Jan-24 | Grant | 62,500 | -- | -- | 87% 71.56K to 134.06K | |
| 03-Jan-24 5:22 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 01-Jan-24 | Grant | 62,500 | -- | -- | 90% 69.43K to 131.93K | |
| 15-Dec-23 5:08 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 13-Dec-23 | Grant | 225,000 | -- | -- | 487% 46.17K to 271.17K | |
| 15-Dec-23 5:09 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 13-Dec-23 | Grant | 62,500 | -- | -- | 254% 24.6K to 87.1K | |
| 15-Dec-23 5:10 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 13-Dec-23 | Grant | 62,500 | -- | -- | 690% 9.05K to 71.56K | |
| 15-Dec-23 5:11 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 13-Dec-23 | Grant | 62,500 | -- | -- | 902% 6.93K to 69.43K | |
| 04-Dec-23 4:30 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 30-Nov-23 | Grant | 2,284 | $2.81 | $6,426.03 | 5% 43.88K to 46.17K | |
| 17-Nov-23 5:03 PM View: | Lepore Patrick G Director | Vyne Therapeutics Inc. (VYNE) | 15-Nov-23 | Purchase | 13,000 | $3.91 | $50,778.00 | 55% 23.47K to 36.47K | |
| 04-Oct-23 4:21 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 02-Oct-23 | Payment of Exercise | 1,154 | $3.83 | $4,419.82 | (4%) 25.75K to 24.6K | |
| 04-Oct-23 4:23 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 02-Oct-23 | Payment of Exercise | 1,184 | $3.83 | $4,534.72 | (12%) 10.24K to 9.05K | |
| 04-Oct-23 4:26 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 02-Oct-23 | Payment of Exercise | 1,087 | $3.83 | $4,163.21 | (14%) 8.02K to 6.93K | |
| 04-Oct-23 4:19 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 02-Oct-23 | Payment of Exercise | 8,549 | $3.83 | $32,742.70 | (16%) 52.43K to 43.88K | |
| 05-Jul-23 4:30 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 30-Jun-23 | Payment of Exercise | 981 | $4.10 | $4,022.10 | (2%) 53.41K to 52.43K | |
| 05-Jul-23 4:32 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 30-Jun-23 | Payment of Exercise | 157 | $4.10 | $643.70 | (< 1%) 25.91K to 25.75K | |
| 05-Jul-23 4:34 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 30-Jun-23 | Payment of Exercise | 151 | $4.10 | $619.10 | (1%) 10.39K to 10.24K | |
| 05-Jul-23 4:37 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 30-Jun-23 | Payment of Exercise | 91 | $4.10 | $373.10 | (1%) 8.11K to 8.02K | |
| 02-Jun-23 4:34 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 31-May-23 | Grant | 3,664 | $3.46 | $12,663.90 | 16% 22.24K to 25.91K | |
| 02-Jun-23 4:31 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 31-May-23 | Grant | 2,766 | $3.46 | $9,560.13 | 5% 50.65K to 53.41K | |
| 04-Apr-23 5:01 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 31-Mar-23 | Payment of Exercise | 2,734 | $3.08 | $8,420.72 | (5%) 53.38K to 50.65K | |
| 04-Apr-23 5:05 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 31-Mar-23 | Payment of Exercise | 480 | $3.08 | $1,478.40 | (4%) 10.87K to 10.39K | |
| 04-Apr-23 5:07 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 31-Mar-23 | Payment of Exercise | 384 | $3.08 | $1,182.72 | (5%) 8.49K to 8.11K | |
| 04-Apr-23 5:03 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 31-Mar-23 | Payment of Exercise | 478 | $3.08 | $1,472.24 | (2%) 22.72K to 22.24K | |
| 22-Mar-23 4:01 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 20-Mar-23 | Purchase | 10,000 | $2.50 | $25,000.00 | 79% 12.72K to 22.72K | |
| 22-Mar-23 4:03 PM View: | Lepore Patrick G Director | Vyne Therapeutics Inc. (VYNE) | 20-Mar-23 | Purchase | 20,000 | $2.48 | $49,680.00 | 576% 3.47K to 23.47K | |
| 04-Jan-23 5:03 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 31-Dec-22 | Payment of Exercise | 10,685 | $0.15 | $1,602.75 | (< 1%) 1.07M to 1.06M | |
| 04-Jan-23 5:09 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 31-Dec-22 | Payment of Exercise | 1,720 | $0.15 | $258.00 | (< 1%) 221.97K to 220.25K | |
| 04-Jan-23 5:05 PM View: | Zeronda Tyler Chief Financial Officer | Vyne Therapeutics Inc. (VYNE) | 31-Dec-22 | Payment of Exercise | 354 | $0.15 | $53.10 | (< 1%) 173.36K to 173.0K | |
| 04-Jan-23 5:12 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 31-Dec-22 | Payment of Exercise | 1,813 | $0.15 | $271.95 | (< 1%) 230.96K to 229.14K | |
| 02-Dec-22 10:00 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 30-Nov-22 | Grant | 34,705 | $0.20 | $6,861.18 | 3% 1.04M to 1.07M | |
| 04-Oct-22 5:04 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 30-Sep-22 | Payment of Exercise | 1,813 | $0.22 | $404.30 | (< 1%) 232.77K to 230.96K | |
| 04-Oct-22 5:00 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 30-Sep-22 | Payment of Exercise | 10,683 | $0.22 | $2,382.31 | (1%) 1.05M to 1.04M | |
| 04-Oct-22 5:05 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 30-Sep-22 | Payment of Exercise | 1,719 | $0.22 | $383.34 | (< 1%) 223.69K to 221.97K | |
| 04-Oct-22 5:05 PM View: | Zeronda Tyler CFO | Vyne Therapeutics Inc. (VYNE) | 30-Sep-22 | Payment of Exercise | 353 | $0.22 | $78.72 | (< 1%) 173.71K to 173.36K | |
| 05-Jul-22 5:00 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 30-Jun-22 | Payment of Exercise | 10,683 | $0.39 | $4,155.69 | (1%) 1.06M to 1.05M | |
| 05-Jul-22 5:01 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 30-Jun-22 | Payment of Exercise | 1,719 | $0.39 | $668.69 | (< 1%) 225.41K to 223.69K | |
| 05-Jul-22 5:01 PM View: | Zeronda Tyler CFO | Vyne Therapeutics Inc. (VYNE) | 30-Jun-22 | Payment of Exercise | 354 | $0.39 | $137.71 | (< 1%) 174.07K to 173.71K | |
| 05-Jul-22 5:00 PM View: | Harsch Mutya Chief Legal Officer and GC | Vyne Therapeutics Inc. (VYNE) | 30-Jun-22 | Payment of Exercise | 1,813 | $0.39 | $705.26 | (< 1%) 234.58K to 232.77K | |
| 02-Jun-22 4:36 PM View: | Zeronda Tyler CFO | Vyne Therapeutics Inc. (VYNE) | 31-May-22 | Grant | 12,510 | $0.35 | $4,332.21 | 8% 161.56K to 174.07K | |
| 02-Jun-22 4:35 PM View: | Domzalski David President and CEO Director | Vyne Therapeutics Inc. (VYNE) | 31-May-22 | Grant | 11,887 | $0.35 | $4,116.47 | 1% 1.05M to 1.06M | |
| 04-Apr-22 5:09 PM View: | Stuart Iain Chief Scientific Officer | Vyne Therapeutics Inc. (VYNE) | 31-Mar-22 | Payment of Exercise | 3,469 | $0.65 | $2,254.85 | (2%) 228.88K to 225.41K |
